institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

Twice-Yearly HIV Prevention Injection Approved by FDA | UNC-Chapel Hill

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, in June. The injection, which boasts a six-month-long period of effective protection, will help mitigate health care access gaps and prevent further infections brought on by low medication adherence. Dr. Joe Eron, the Herman and Louise Smith Distinguished Professor of Medicine and director of the clinical core at the UNC Center for AIDS Resear…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

7 Articles

The World Health Organization (WHO) recommended Gilead Lenacapavir , an injection given twice a year as a tool to prevent HIV infection. How effective is the drug? Is it available outside the United States? Side Effects The recommendation, issued at the International AIDS Conference in Kigali, Rwanda occurs almost a month after the U.S. health authority approves the drug, giving patients new hopes to stop transmission of the virus.

Noticias de NavarraNoticias de Navarra
+2 Reposted by 2 other sources

The Director General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, reported on Wednesday that WHO and its partners are working with nine countries so that nearly two million people can access Lenacapavir injection - a drug for HIV prevention - at a lower negotiated price.

·Pamplona, Spain
Read Full Article

The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, reported on Wednesday that WHO and its partners are working with nine countries so that nearly two million people can access lenacapavir injection - a drug for HIV prevention - at a lower negotiated price.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Tuesday, July 22, 2025.
Sources are mostly out of (0)